Abstract
Objective:
To compare changes in weight in obese patients who received long-acting octreotide (octreotide LAR) at one of three dose levels (20, 40, or 60 mg) or placebo over 6 months and to identify the lowest dose of octreotide LAR that safely achieved optimal weight loss.
Design:
Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.
Patients:
A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30–65 kg/m2) and evidence of insulin hypersecretion were enrolled. Patients were predominantly either Caucasian (50.0%) or African American (45.3%). The mean age (38±11 year), weight (110.7±23 kg), and BMI (39.8±6.5 kg/m2) were similar across the four treatment groups.
Measurements:
Efficacy measures included weight, BMI, fasting serum glucose; triglycerides; percentage of total body fat and abdominal fat as measured by dual-energy X-ray absorptiometry; skin fold thickness; waist-to-hip circumference; leptin; percentage of carbohydrates, fat, and protein ingested; nutritional evaluation (including dietary analysis – 3-day food record); quality of life (QoL; using the Impact of Weight on Quality of Life-Lite™); Beck Depression Inventory; and Carbohydrate Craving Questionnaire. Safety measures included medical history, vital signs, physical examinations, hematology, blood chemistries, thyroid function tests, hemoglobin A1c, gallbladder ultrasound, electrocardiograms, and adverse events.
Results:
After 6 months of treatment, patients receiving 40 or 60 mg of octreotide LAR experienced statistically significant weight loss compared to baseline, with mean differences from placebo in percent weight change of −1.98 and −1.87%, respectively. This finding was accompanied by statistically significant mean decreases in BMI compared to baseline, that is, a mean decrease of 0.73 and 0.79 kg/m2 for the 40 and 60 mg treatment arms, respectively. The observed weight loss was progressive during the 6-month treatment in the two higher dose groups. The lowest dose to reach statistical significance in weight loss after 6 months' treatment was 40 mg. Post hoc analysis revealed a 3.5–3.8% weight loss at month 6 in the two higher dose groups among Caucasian patients having insulin secretion greater than the median of the cohort, defined as CIRgp (corrected insulin response at the glucose peak) ⩾1.43. There were no statistically significant changes in QoL scores, body fat, leptin concentration, Beck Depression Inventory, or macronutrient intake. Mean changes of blood glucose AUC0–180 min during an oral glucose tolerance test in patients taking octreotide LAR were 39–40 mg/dl h higher than those on placebo. A total of 7–21% of the patients taking octreotide LAR reached a 5% or greater decrease in body weight from Baseline, compared to 11% for the placebo group. This was not statistically significant. The most common adverse events included diarrhea, headache, cholelithiasis, nausea, and abdominal pain.
Conclusion:
Octreotide LAR given at 40 or 60 mg resulted in statistically significant weight loss. A post hoc analysis stratifying patients by race and CIRgp indicated that Caucasian patients with the greater degree of insulin hypersecretion appeared to derive the most benefit from treatment. The observed safety profile was consistent with the known effects of octreotide from previous studies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76–79.
Bray GA . Health hazards of obesity. Endocrinol Metab Clin NA 1996; 25: 907–919.
Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath Jr CW . Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999; 341: 1097–1105.
Kopelman PG . Obesity as a medical problem. Nature 2000; 404: 635–643.
Myers A, Rosen JC . Obesity stigmatization and coping: relation to mental health symptoms, body image, and self-esteem. Int J Obes Relat Metab Disord 1999; 23: 221–230.
Bray GA, Gray DS . Treatment of obesity: an overview. Diab Metab Rev 1998; 4: 653–679.
Bray GA, Greenway FL . Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20: 805–875.
Consensus development conference panel, NIH Conference. Gastrointestinal surgery for severe obesity. Ann Int Med 1991; 115: 956–961.
Lustig RH . The neuroendocrinology of obesity. Endocrinol Metab Clin NA 2001; 30: 765–785.
Sigal RJ, El-Hashimy M, Martin BC . Acute post-challenge hyperinsulinemia predicts weight gain. Diabetes 1997; 46: 1025–1029.
Meistas MT, Margolis S, Kowarski AA . Hyperinsulinemia of obesity is due to decreased clearance of insulin. Am J Physiol 1983; 245: E155–E159.
Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G . Insulin resistance and hypersecretion in obesity. European group for the study of insulin resistance (EGIR). J Clin Invest 1997; 100: 1166–1173.
Lustig RH . Hypothalamic obesity: the sixth cranial endocrinopathy. Endocrinologist 2002; 12: 210–217.
Gilon P, Henquin JC . Mechanisms and physiological significance of the cholinergic control of pancreatic β-cell function. Endocrine Rev 2001; 22: 565–604.
Sluiter WJ, Erkelens DW, Terpstra P, Reitsma WD, Doorenbos H . Glucose intolerance and insulin release, a mathematical approach. 1. Assay of the beta cell response after glucose loading. Diabetes 1976; 25: 241–244.
Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ . Drug therapy: octreotide. N Engl J Med 1996; 334: 246–254.
Krentz AJ, MacDonald LM, Schade DS . Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism 1994; 43: 24–31.
Haqq AM, Stadler DD, Rosenfeld RG, Pratt KL, Weigle DS, Frayo FS et al. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children in Prader–Willi syndrome. J Clin Endocrinol Metab 2003; 88: 3573–3576.
Lustig RH, Rose SR, Burghen GA, Velasquez-Mieyer P, Broome DC, Smith K et al. Hypothalamic obesity in children caused by cranial insult: altered glucose and insulin dynamics, and reversal by a somatostatin agonist. J Pediatr 1999; 135: 162–168.
Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2003; 88: 2586–2592.
Velasquez-Mieyer PA, Cowan PA, Arheart KL, Buffington CK, Spencer KA, Connelly BE et al. Suppression of insulin secretion promotes weight loss and alters macronutrient preference in a subset of obese adults. Int J Obes Relat Metab Disord 2003; 27: 219–226.
Declaration of Helsinki. Recommendation guiding medical physicians in biomedical research involving human subjects. Republic of South Africa Revision, October 1996.
International Conference on Harmonization (ICH). Guideline for good clinical practice. As part of the ICH Harmonized Tripartite Guideline (European Union, Japan, and USA). ICH Harmonized Tripartite Guideline, 1996.
Kolotkin RL, Crosby RD, Kosloski KD, Williams GR . Development of a brief measure to assess quality of life in obesity. Obes Res 2001; 9: 102–111.
Rom DM, Costello RJ, Connell LT . On closed test procedures for dose–response analysis. Stat Med 1994; 13: 1583–1596.
Tukey JW, Ciminera JL, Heyse JP . Testing the statistical certainty of a response with increasing doses of a compound. Biometrics 1985; 41: 295–301.
Preeyasombat C, Bacchetti P, Lazar AA, Lustig RH . Racial and etiopathologic dichotomies in insulin hypersecretion and resistance in obese children. J Pediatr 2005; 146: 474–481.
Velasquez-Mieyer PA, Cowan PA, Umpierrez GE, Lustig RH, Cashion AK, Burghen GA . Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance testing in obese subjects. Int J Obes Relat Metab Disord 2003; 27: 1359–1364.
Lustig RH . Autonomic dysfunction of the β-cell and the pathogenesis of obesity. Rev Endocrinol Metab Dis 2003; 4: 23–32.
Velasquez-Mieyer PA, Umpierrez GE, Lustig RH, Cashion AK, Cowan PA, Christensen M et al. Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults. Int J Obes Relat Metab Disord 2004; 28: 1–4.
Gower BA, Granger WM, Franklin F, Shewchuk RM, Goran MI . Contribution of insulin secretion and clearance to glucose-induced insulin concentration in African-American and Caucasian children. J Clin Endocrinol Metab 2002; 87: 2218–2224.
Jiang Z, Srinivasan SR, Radkakrishnamurthy B, Dalferes ER, Berenson GS . Racial (black–white) differences in insulin secretion and clearance in adolescents: the Bogalusa Heart Study. Pediatrics 1996; 97: 357–360.
Yanovski JA, Yanovski SZ, Filmer KM, Hubbard VS, Avila N, Lewis B et al. Differences in body composition of black and white girls. Am J Clin Nutr 1996; 64: 833–839.
Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Int Med 1992; 117: 711–718.
Moschetta A, Stolk MF, Rehfeld JF, Portincasa P, Slee PH, Koppeschaar HP et al. Severe impairment of postprandial cholecystokinin release and gallbladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Aliment Pharmacol Ther 2001; 15: 181–185.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lustig, R., Greenway, F., Velasquez-Mieyer, P. et al. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes 30, 331–341 (2006). https://doi.org/10.1038/sj.ijo.0803074
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0803074
Keywords
This article is cited by
-
Metabolic actions of the growth hormone-insulin growth factor-1 axis and its interaction with the central nervous system
Reviews in Endocrine and Metabolic Disorders (2022)
-
Effects of micro-nano bubble with CO2 treated water on the growth of Amaranth green (Amaranthus viridis)
Environmental Science and Pollution Research (2022)
-
Insulin translates unfavourable lifestyle into obesity
BMC Medicine (2018)
-
Social behavioural epistemology and the scientific community
Journal of Genetics (2017)
-
Suppression of hyperinsulinaemia in growing female mice provides long-term protection against obesity
Diabetologia (2015)